Patents Examined by Patrick T. Lewis
  • Patent number: 11911408
    Abstract: The present disclosure provides a pharmaceutical composition comprising i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic. Kits utilizing i) an A1 adenosine receptor (A1AR) agonist, ii) an A1AR antagonist, and iii) an anticholinergic are also provided, as well as methods utilizing the described pharmaceutical compositions and kits.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: February 27, 2024
    Assignee: UNIVERSITY OF ALASKA FAIRBANKS
    Inventors: Bernard Laughlin, Kelly Drew
  • Patent number: 11896594
    Abstract: The present invention is directed to a palatable, hard chewable composition comprising a therapeutically effective amount of a veterinary acceptable isoxazoline, a stabilized macrocyclic lactone, an acceptable salt form of pyrantel, at least one natural animal based palatant, and at least one veterinary acceptable excipient; and methods for treating or preventing a parasitic infection or infestation in an animal in need thereof with said composition.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: February 13, 2024
    Assignee: Zoetis Services LLC
    Inventors: Sachin Pundlik Kolhe, Supriya Gautam Thakur
  • Patent number: 11890297
    Abstract: The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (b) an adenosine derivative disclosed herein. Compositions comprising an effective amount of an adenosine derivative and an effective amount of a capsid (CA) inhibitor are also provided.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: February 6, 2024
    Assignee: Brii Biosciences, Inc.
    Inventors: Lianhong Xu, Zhi Hong
  • Patent number: 11890296
    Abstract: An object of the present invention is to provide a combination drug containing cytarabine and a DHODH inhibitor, as a new anti-tumor agent, and to provide an anti-tumor effect enhancing agent which is used in combination with cytarabine, an anti-tumor kit, and an anti-tumor agent which is used in combination with cytarabine. According to the present invention, an anti-tumor agent and an anti-tumor kit containing cytarabine and a dihydroorotate dehydrogenase inhibitor compound are provided.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 6, 2024
    Assignee: FUJIFILM Corporation
    Inventors: Satoshi Kitazawa, Yukiko Ishii, Koichi Saito, Shun Matsuda
  • Patent number: 11891602
    Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: February 6, 2024
    Assignee: Toray Industries, Inc.
    Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
  • Patent number: 11883367
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: January 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Patent number: 11878027
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Patent number: 11873319
    Abstract: Methods and compositions are provided for increasing the production of a type I interferon (IFN) in a cell. Aspects of the methods include increasing the level of a 2?-5? phosphodiester linkage comprising cyclic-di-nucleotide in a cell in a manner sufficient to increase production of the type I interferon (IFN) by the cell. Also provided are compositions and kits for practicing the embodiments of the methods.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 16, 2024
    Assignee: The Regents of the University of California
    Inventors: Russell E. Vance, Ming C. Hammond, Dara Burdette, Elie J. Diner, Stephen C. Wilson
  • Patent number: 11873487
    Abstract: The disclosure provides novel methods and compositions for gene editing. In particular, the disclosure relates to compositions and methods of making nucleic acid donor templates for highly efficient and precise gene editing.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: January 16, 2024
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Craig Mello, Krishna Sumanth Ghanta
  • Patent number: 11865132
    Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: January 9, 2024
    Assignee: ASCLETIS BIOSCIENCE CO., LTD.
    Inventors: Bin Liang, Bailing Yang, Yang Lai, Jinzi Jason Wu
  • Patent number: 11858953
    Abstract: The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: January 2, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: John Chaput, Jen-Yu Liao, Saikat Bala
  • Patent number: 11858931
    Abstract: The invention relates to compounds of formula (A): or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?V?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 2, 2024
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Katerina Leftheris, Maureen Reilly, Darren Finkelstein, Nicole Cooper, Christopher Bailey, Jacob Cha
  • Patent number: 11857532
    Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: January 2, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
  • Patent number: 11851700
    Abstract: Disclosed are methods, compositions and kits for contacting a sample containing a biological particle with a catalyst associated with or attached to a support. The biological particle may be cells and/or nuclei. The catalyst may be an enzyme configured to digest an extracellular molecule, such as an extracellular biological molecule, including extracellular nucleic acid molecules. In some examples, the biological particle is an aggregate of cells that is processed to single cells with a nuclease that is attached to a bead support. The bead and nuclease may subsequently be removed from the system. The single cells that result from the method can be used in single cell-based droplet systems for obtaining genome or transcriptome profiles of single cells.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: December 26, 2023
    Assignee: 10X GENOMICS, INC.
    Inventors: Felice Alessio Bava, Geoffrey McDermott
  • Patent number: 11834470
    Abstract: This disclosure provides a method of synthesis of 4?-thioribose NAD+ and analogues thereof, using an efficient chemoenzymatic approach. Also provided are methods of inhibiting the CD38 enzyme and compounds including 4?-thioribose NAD+ and compounds related thereto.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: December 5, 2023
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Yong Zhang, Zhefu Dai, Xiao-Nan Zhang
  • Patent number: 11833167
    Abstract: The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase intracellular NAD+ levels, and can enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: December 5, 2023
    Assignee: MitoPower LLC
    Inventors: Gangadhara Ganapati, Atignal Shankara Rao Arvind
  • Patent number: 11826379
    Abstract: A method of treatment for coronavirus disease 2019 (COVID-19) is disclosed herein. The method comprises administering a therapeutically effective dose of a combination of ribavirin and minocycline. A pharmaceutical composition comprising ribavirin and minocycline is also disclosed herein. The pharmaceutical composition may further include one or more pharmaceutical excipients.
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: November 28, 2023
    Inventor: Rafi Israel
  • Patent number: 11819512
    Abstract: Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form of Compound I and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 21, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jenna Leigh Jeffrey, Kenneth V. Lawson, Dillon Harding Miles
  • Patent number: 11813271
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: November 14, 2023
    Assignee: LifeScience AS
    Inventor: Jan Remmereit
  • Patent number: 11813277
    Abstract: Methods and agents for modulating intracellular coenzyme A levels are described for therapeutic purposes. Increasing intracellular coenzyme A increases alternate macrophage activation resulting in suppression or resolution of an immune response for benefit in treating inflammatory diseases. Decreasing intracellular coenzyme A levels decreases alternate macrophage activation which is beneficial in treating NASH/NAFLD and various fibrotic diseases as well as reversing immune suppressing activity of tumor-associated immune cells such as macrophages for the treatment of cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 14, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ajit Srinivas Divakaruni, Steven J. Bensinger, Anne Neville Murphy, Wei Yuan Hsieh